Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$8.96 ▼ DOWN 3.34% (−$0.31)About Certara, Inc.
https://www.certara.com ↗Certara, Inc. provides biosimulation software and services for drug discovery, development, regulatory approval, and market access, serving biopharma, academia, and government worldwide.
INDUSTRY
A PRODUCT CERTARA, INC. IS KNOWN FOR
An AI-enabled QSP platform that integrates advanced tech and validated models to make quantitative systems pharmacology more accessible and scalable, empowering scientific teams to make better data-driven decisions in drug discovery and development.
Certara in 2025
Certara Stock Surges Over 22% as FDA Prioritizes Biosimulation, Shifting Away from Animal Testing
Certara's stock price experienced a significant surge following the FDA's announcement of a strategic shift towards using New Approach Methodologies (NAMs), such as biosimulation, to replace animal testing for monoclonal antibodies. This regulatory tailwind, combined with a key update to Certara's flagship Simcyp™ Simulator, positioned the company as a primary beneficiary of this industry-wide evolution, attracting substantial investor attention and analyst upgrades.
Certara Appoints New CEO Jon Resnick to Steer Future Growth
Certara announced the appointment of Jon Resnick as the new Chief Executive Officer, succeeding William Feehery. This move signals a strategic leadership transition intended to drive innovation and growth, leveraging Resnick's extensive experience in scaling market-leading life sciences technology companies. [1, 2, 27]
RATINGS SNAPSHOT
Overall rating: C+
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 TWST | $173.83 | COMPARE |
 TXG | $83.30 | COMPARE |
 AVAH | $12.21 | COMPARE |
 CLOV | $4.63 | COMPARE |
 VCEL | $40.53 | COMPARE |
 PGNY | $25.91 | COMPARE |
 SDGR | $27.13 | COMPARE |
 OMCL | $35.17 | COMPARE |